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Abstract 23 
We investigated the effects of supplement identification on exercise performance with 24 
caffeine supplementation. Forty-two trained cyclists (age 37±8 y, body mass [BM] 25 
74.3±8.4 kg, height 1.76±0.06 m, maximum oxygen uptake 50.0±6.8 ml·kg-1·min-1) 26 
performed a ~30 min cycling time-trial 1 h following either 6 mg·kg-1BM caffeine 27 
(CAF) or placebo (PLA) supplementation and one control (CON) session without 28 
supplementation. Participants identified which supplement they believed they had 29 
ingested (“caffeine”, “placebo”, “don’t know”) pre- and post-exercise. Subsequently, 30 
participants were allocated to subgroups for analysis according to their identifications. 31 
Overall and subgroup analyses were performed using mixed-model and magnitude 32 
based inference analyses. Caffeine improved performance vs. PLA and CON 33 
(P≤0.001). Correct pre- and post-exercise identification of caffeine in CAF improved 34 
exercise performance (+4.8 and +6.5%) vs. CON, with slightly greater relative 35 
increases than the overall effect of caffeine (+4.1%). Performance was not different 36 
between PLA and CON within subgroups (all P>0.05), although there was a tendency 37 
towards improved performance when participants believed they had ingested caffeine 38 
post-exercise (P=0.06; 87% likely beneficial). Participants who correctly identified 39 
placebo in PLA showed possible harmful effects on performance compared to CON. 40 
Supplement identification appeared to influence exercise outcome and may be a 41 
source of bias in sports nutrition.  42 
Key words: Placebo effect; nocebo effect; expectancy; exercise performance; 43 
caffeine supplementation; supplement identification; cycling time-trial 44 
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Introduction 46 
Contemporary investigations into the effects of nutritional interventions on exercise 47 
generally employ double-blind and placebo controlled study designs to ensure there is 48 
no bias from the prior knowledge of which substance has been ingested and that 49 
comparisons can be made against an appropriate control. The placebo effect, namely a 50 
positive outcome brought about purely from the belief that one has received a positive 51 
intervention (Clark et al., 2000), can mask the true effect of an intervention. The 52 
nocebo effect is directly opposite to this in that a negative outcome occurs following 53 
the administration of an intervention (Benedetti et al., 2007; (Lundby et al,, 2012; 54 
Pollo et al., 2012).  55 
 56 
Caffeine-based investigations can be difficult to blind due to the associated side-57 
effects at high doses (i.e., >2-3 mg·kg-1BM), namely tachycardia and agitation 58 
(Graham & Spriet, 1995), and common knowledge thereof. Once an individual 59 
believes that they have ingested a performance enhancing substance, several 60 
behaviours may be modified that can contribute to exercise performance (Beedie et 61 
al., 2006). This may lead to many of the participants beginning exercise with a greater 62 
expectancy due to the occurrence of physiological side effects making it difficult to 63 
separate the true effect of caffeine from its associated placebo effect. However, most 64 
studies do not control whether blinding of the intervention was successful; 65 
determination of an individual’s belief of what they have ingested prior to exercise 66 
may lead to further investigation into the effects of preconceptions (placebo effect) on 67 
exercise.  68 
 69 
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In addition to preconceptions, it would be reasonable to suggest that any behavioural 70 
processes that might have been modified prior to exercise might also change 71 
throughout exercise on the basis of new information (Beedie et al., 2006). This might 72 
relate to an individual’s perceived effort throughout exercise, which may or may not 73 
be influenced by the intervention itself. An individual who believed they had ingested 74 
placebo prior to exercise but then changes opinion due to a good start may influence 75 
their pacing accordingly throughout the test. Conversely, someone who expects to 76 
improve performance due to preconceived opinion of ingesting the active substance, 77 
but subsequently struggles to perform, might suffer a reduction in performance due to 78 
a further lack of motivation. Therefore, it would also be of interest to determine the 79 
individual’s perception of what was ingested following exercise to determine whether 80 
the initial opinion has been modified throughout the protocol.  81 
 82 
Therefore, to advance the knowledge on the influence of the placebo effect in sports 83 
nutrition, we investigated the effect of supplement identification following caffeine 84 
ingestion on exercise performance. We hypothesised that caffeine supplementation 85 
would improve exercise performance regardless of proper identification, and that 86 
improvements would be greatest in those who correctly guessed they had taken 87 
caffeine, while participants ingesting placebo but guessed they had ingested caffeine 88 
would also improve their exercise performance.  89 
90 
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Materials and Methods 91 
Participants 92 
Forty-two trained male cyclists (Table 1) volunteered and gave their written informed 93 
consent to participate in this study. The exclusion criteria included the use of beta-94 
alanine and creatine in the past 6 months, the presence of any musculoskeletal 95 
disorder, or the current or past use of anabolic steroids or other illicit performance-96 
enhancing drugs. Habitual caffeine consumption (Table 1) was assessed prior to 97 
inclusion in the study via a Food Frequency Questionnaire adapted from two 98 
previously developed and validated questionnaires (Bühler et al., 2014 and Fred 99 
Hutchinson Cancer Research Center, 2004). Although these data were not used to 100 
exclude any participant per se, any participant ingesting caffeine as a dietary 101 
supplement was not included in the study since these individuals may or may not have 102 
been more susceptible to correct supplement identification due to experience. The 103 
study was approved by the University of São Paulo’s Ethics Review Committee as 104 
part of a larger thematic project, the remaining data of which is presented elsewhere. 105 
 106 
Experimental Design 107 
All participants attended the laboratory on six separate occasions following a 108 
minimum 6-h fasting period. All trials were performed at the same time of day for 109 
each participant (between 08:00 and 20:00) to ensure results were not affected by 110 
circadian variation (Reilly and Brooks, 1986). All tests were performed on a cycle 111 
ergometer (Lode Excalibur, Germany) and separated by a minimum of 72 h. The first 112 
session comprised of an incremental cycling test to exhaustion to determine VO2max 113 
and maximal cycling output (Wmax). In the remaining five sessions, participants 114 
performed a simulated time trial, namely two familiarisation sessions and three main 115 
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trials (caffeine - CAF, placebo - PLA, and control - CON). Twenty-four hours prior to 116 
the main trials, participants were required to refrain from alcohol, caffeine and any 117 
unaccustomed strenuous exercise. Food intake was monitored during the 24-h period 118 
prior to the main trials using a food diary. Food diaries were analysed by a nutritionist 119 
immediately prior to the experimental sessions to ensure that participants had not 120 
consumed any caffeine containing foods while energy and macronutrient intake was 121 
analysed at a later time by the same nutritionist using specific software (Avanutri 122 
online, Avanutri, Rio de Janeiro, Brazil).  123 
 124 
Main trials were performed in a double-blind, randomised, counterbalance and cross-125 
over manner. For the CAF and PLA trials, participants ingested a capsule containing 126 
either 6 mg∙kg-1BM of caffeine or dextrose alongside 500 mL of water. Participants 127 
were then required to remain seated for 1 h prior to the commencement of the main 128 
exercise protocol. During the CON trial, participants followed the same procedures 129 
although they did not consume any capsule prior to exercise. Participants were 130 
allowed access to their phones or own reading material throughout this waiting 131 
period. Blinding occurred via an outside researcher who prepared each participant’s 132 
supplements in identical looking opaque capsules. Participants were randomly 133 
assigned to each experimental condition using a Latin Square model (Mason et al., 134 
2003). 135 
 136 
In each supplementation trial, participants were required to respond to a standardised 137 
question immediately prior to exercise (i.e. 1 h post-supplement ingestion) and again 138 
immediately following completion of the exercise. The question related to their belief 139 
of which supplement they had taken and was given with the option of choosing one of 140 
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three possible answers (i.e. “Which supplement do you think you have ingested?” a) 141 
Caffeine b) Placebo c) Don’t know). They were also asked to state the reason they had 142 
chosen their answer (Supplementary Tables 1 and 2). Based upon each participant’s 143 
answer, subgroups were composed according to the supplement trial (i.e. CAF or 144 
PLA), supplement identification (i.e. “correct; “don’t know”; “wrong”), and the 145 
moment in which the question was answered (i.e. Pre-exercise identification; Post-146 
exercise identification).     147 
 148 
Experimental Procedures 149 
Incremental cycling capacity test 150 
Each participant performed a graded cycle capacity test to exhaustion on a cycle 151 
ergometer (Lode Excalibur, Germany) to determine individual VO2max and Wmax. 152 
Individual set up of the cycle ergometer (saddle and handlebar height and length) was 153 
determined prior to the maximal test, recorded electronically and maintained for all 154 
subsequent trials. Participants were required to perform four submaximal 4-min stages 155 
starting at 75 W; this was increased by 50 W each stage until 225 W. Thereafter, 156 
workload was increased by 30 W every minute until volitional exhaustion. Ventilatory 157 
and gas exchange measurements were recorded using a portable breath-by-breath 158 
system (K4 b2, Cosmed, Italy) which has previously been validated (McLaughlin et 159 
al., 2001); the highest value averaged over a 30-s period during the test was defined as 160 
VO2max. The last completed stage plus the fraction of time spent in the final non-161 
completed stage multiplied by 30 W was defined as a participant’s Wmax. 162 
 163 
Cycling Time-Trial (TT) 164 
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The cycling TT was performed on a cycle ergometer (Lode Excalibur, Germany). 165 
Participants were required to perform a 5-min cycling warm up performed at 125 W 166 
followed immediately by the TT. Participants performed the TT in which they were 167 
required to complete a predetermined amount of work equivalent to 25 min at 85% of 168 
their individual Wmax in the fastest possible time; this was based on the protocol of 169 
Jeukendrup et al. (2008). 170 
The formula for total amount of work to be performed was as follows: 171 
Total amount of work = 0.85 × Wmax × 1500 s 172 
The average amount of work to be completed for all participants was 420.3 ± 68.6 kJ. 173 
The cycle ergometer was set in linear mode, meaning work load was cadence-174 
dependent according to the formula: 175 
W = α × (rev·min-1)2 176 
The α value was based on each participant’s Wmax so that they were working at 85% 177 
Wmax when cycling at a cadence of 95 rev·min
-1. Participants were instructed to 178 
complete the exercise in the fastest possible time. No motivation or specific 179 
information was given to the participants during the test although they were informed 180 
when they had completed 25%, 50%, 75% and 90% of the exercise. Mean power 181 
output (MPO, W) was recorded as the outcome measure for the TT. In order to 182 
determine the reliability of the test, we conducted a further test-retest study on 50 183 
participants who completed the TT on two occasions. There was no significant 184 
difference in MPO between tests (227.2 ± 35.4 and 224.5 ± 34.7W) with a coefficient 185 
of variation of 3.0 ± 2.3%.    186 
 187 
Statistical Analysis 188 
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Exercise data (MPO) was compared by mixed model analysis in order to determine 189 
the effect of supplementation on exercise. To ensure there was no learning effect, the 190 
effect of trial order was determined with trial considered a fixed factor and 191 
participants a random factor. For the overall analysis, supplementation was assumed 192 
as a fixed factor and participants as a random factor. To investigate the effect of 193 
expectation on exercise, further sub-analyses were performed according to pre- and 194 
post-exercise responses to the questionnaire. Participants were grouped according to 195 
their supplement identification (“correct”; “don’t know”; “wrong”) in CAF and PLA 196 
and subsequent exercise data within these subgroups was compared to CON. Analyses 197 
of these data were performed in an identical manner to the overall data, assuming 198 
supplementation as a fixed factor and participant as a random factor. Tukey post-hoc 199 
tests were performed whenever a significant F-value was obtained and the 200 
significance level was previously set at P ≤ 0.05. All these analyses were conducted 201 
using SAS software (SAS® version 9.3, Cary, NC, USA) and are presented as mean ± 202 
1SD unless otherwise stated. Magnitude based inferences (MBI; Batterham and 203 
Hopkins, 2006) were used to determine the practical significance of caffeine on TT 204 
performance using a spreadsheet to establish the likelihood of a meaningful effect on 205 
exercise capacity. The smallest worthwhile improvement in MPO was calculated 206 
using half the CV of the test (Hopkins, 2004; Paton and Hopkins, 2006). Qualitative 207 
descriptors were assigned to the positive percentile scores as follows: <1%, almost 208 
certainly not; 1-5%, very unlikely; 5-25%, unlikely; 25-75%, possibly; 75-95%, likely; 209 
95-99%, very likely; >99%, almost certainly (Hopkins, 2002). Additionally, the 210 
estimated means and SDs from CAF and PLA, separated according to supplement 211 
identification, were used to calculate Cohen’s d (Cohen, 1988) effect sizes and 212 
confidence intervals (CI) to plot between-trial comparisons. It is important to note that 213 
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direct comparisons could not be made between the overall effects vs. the within 214 
subgroup effects (e.g., “Overall CAF vs. CON” versus any sub-group within CAF) 215 
since this would result in analysis of duplicate data (considering some of the 216 
participants’ data in overall CAF and PLA are also included within their specific sub-217 
groups). Therefore, these comparisons and subsequent interpretation were based upon 218 
MBIs, percentage and absolute changes, and individual responses.  219 
220 
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Results 221 
Questionnaires 222 
Pre-exercise identification 223 
In CAF, seventeen participants correctly identified caffeine, while twelve incorrectly 224 
identified placebo with a further thirteen choosing “don’t know”. Seventeen 225 
participants correctly identified placebo in PLA, eight believed they had ingested 226 
caffeine, and the remaining seventeen chose “don’t know”.  227 
 228 
Post-exercise identification 229 
Twenty participants correctly identified the supplement following exercise in CAF, 230 
while fourteen were incorrect and a further eight chose “don’t know”. Eighteen 231 
participants correctly assumed that they had taken placebo in PLA, while eleven 232 
believed they had ingested caffeine, and thirteen were unsure as to what they had 233 
ingested choosing “don’t know”.  234 
 235 
A total of thirteen and fourteen participants changed their supplement identification in 236 
CAF and PLA from pre- to post-exercise. Six participants correctly identified caffeine 237 
post-exercise having previously been incorrect (“placebo”, N = 3) or choosing “don’t 238 
know” (N = 3). Three participants who had correctly identified caffeine changed their 239 
mind to placebo (N = 1) or “don’t know” (N = 2) following exercise, while four 240 
participants who chose “don’t know” prior to exercise incorrectly guessed that they 241 
had ingested placebo. Six participants changed their previously unsure (“don’t know”, 242 
N = 5) and incorrect (“caffeine”, N = 1) opinions to correctly identify placebo in PLA. 243 
Five participants changed their opinion to “don’t know” (N = 2) and caffeine (N = 3) 244 
having correctly identified placebo prior to exercise. Two participants who chose 245 
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“don’t know” pre-exercise, incorrectly identified caffeine at post-exercise and one 246 
participant changed his pre-exercise identification of “caffeine” to “don’t know” at 247 
post-exercise. 248 
 249 
Exercise results 250 
Overall 251 
There was no effect of trial order on MPO (P = 0.58). There was an overall effect of 252 
supplement on MPO (P = 0.0002) with post hoc analyses revealing an improved 253 
performance in CAF vs. PLA (+3.0 ± 5.8%, 234.2 ± 36.7 vs. 228.0 ± 37.6 W, P = 254 
0.007; 91% likely beneficial) and vs. CON (+4.1 ± 6.2%, 234.2 ± 36.7 vs. 225.7 ± 255 
38.4 W, P = 0.0002; 99% very likely beneficial), but no difference between PLA and 256 
CON (P = 0.50; 24% unlikely beneficial). Twenty-three participants improved above 257 
the variation of the test in CAF and twelve in PLA.  258 
 259 
Pre-exercise identification 260 
Correct supplement identification in CAF resulted in improved MPO (P ≤ 0.001; 261 
100% almost certainly beneficial) compared to CON (Table 2). Similarly, incorrect 262 
identification in CAF resulted in improved performance compared to CON (P = 263 
0.003; 99% very likely beneficial), but there was no difference for participants who 264 
chose “don’t know” (P = 0.95; 16% unlikely beneficial) (Table 2). Effect sizes and 265 
CIs are presented in Figure 1. Eleven of the seventeen participants who correctly 266 
identified caffeine improved above the variation of the test, while four of thirteen 267 
were improved having chosen “don’t know” and eight of twelve having incorrectly 268 
identified placebo (Figure 2). 269 
 270 
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There were no statistical differences in MPO between PLA and CON within 271 
supplement identification subgroups (all P > 0.05; Table 2), although magnitude 272 
based inferences suggested correct identification of “placebo” in PLA led to possibly 273 
harmful effects on performance. Effect sizes and CIs are presented in Figure 1. Four 274 
participants who correctly identified “placebo” showed performance reductions above 275 
the variation of the test. Twelve participants improved above the variation of the test 276 
in PLA; three who correctly identified placebo, five who chose “don’t know” and four 277 
who believed they ingested caffeine (Figure 2). 278 
 279 
Post-exercise identification 280 
Participants who correctly identified caffeine in CAF improved MPO compared to 281 
CON (P ≤ 0.001; 100% almost certainly beneficial; Table 2) Participants who 282 
incorrectly identified placebo in CAF also improved performance compared to CON 283 
(P = 0.03; 90% likely beneficial; Table 2), but there was no difference in performance 284 
in those who did not identify any supplement (P > 0.05; 58% likely trivial; Table 2). 285 
Effect sizes and CIs are presented in Figure 1. Fifteen of the twenty participants who 286 
correctly identified caffeine improved above the variation of the test, while seven of 287 
fourteen improved despite incorrectly identifying placebo. Of the eight who chose 288 
“don’t know”, only one improved performance (Figure 2).  289 
 290 
Performance was not statistically different between PLA and CON for participants 291 
who chose “don’t know” (P > 0.05; Table 2). There was a tendency towards improved 292 
MPO (+3.7 ± 6.3%, P = 0.06; 87% likely beneficial) in those who incorrectly believed 293 
they had ingested caffeine in PLA (Table 2), while MBIs suggested a possibly 294 
harmful effect of correct identification of placebo (-1.6 ± 4.9%) and only a 1% chance 295 
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of being positive. Effect sizes and CIs are presented in Figure 1. Six participants 296 
improved above the variation having incorrectly identified caffeine, while five 297 
improved having chosen “don’t know”. Only one participant improved having 298 
correctly identified placebo while six worsened performance (Figure 2). 299 
 300 
Food intake 301 
Absolute and relative carbohydrate, protein, and fat intake in the 24 h prior to the 302 
main trials were not significantly different (all P > 0.05). Similarly, total caloric 303 
intake was not different prior to any trial (P = 0.93). 304 
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Discussion 305 
This study showed that correct identification of caffeine, particularly post-exercise, 306 
improved cycling performance with greater relative improvements than the overall 307 
effect of caffeine. Furthermore, there was an apparent improved performance in PLA 308 
for participants who believed they had ingested caffeine, although this was based 309 
upon post-exercise supplement identification only, while correct identification of 310 
placebo, both pre- and post-exercise, may possibly have led to performance 311 
impairments.  312 
 313 
This study employed trained cyclists, the majority of whom were competing at 314 
national and international level. Although none took caffeine as a supplement, all 315 
participants were aware of the substance and its purported ergogenic effect. Thus, it is 316 
reasonable to suggest that any individual who identified the supplement ingested as 317 
caffeine will have had the belief that their performance would improve accordingly. 318 
Indeed, correct identification of caffeine ingestion resulted in an improved 319 
performance with greater relative improvements than the overall effect of caffeine 320 
(Pre-exercise: +4.8% and Post-exercise: +6.5% vs. Overall: +4.1%; Figure 2). The 321 
questionnaire allowed an uncertainty regarding which supplement had been ingested 322 
(“don’t know”). Thus, analysing participants who chose this response would 323 
theoretically allow determination of the “true effect” of caffeine since the individual 324 
would not be biased by opinion. Surprisingly, however, performance was unaffected 325 
with caffeine when participants were unsure as to what they had ingested, but was 326 
improved when they incorrectly identified placebo (Table 2). We can only speculate 327 
as to the reason for these unexpected findings; perhaps the physiological mechanisms 328 
by which caffeine improves performance were a greater stimulus in participants 329 
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believing they had ingested a placebo substance, or there may have been an increased 330 
motivation in these participants. Nonetheless, this was not directly measured here 331 
though future investigation should consider this.   332 
 333 
Interestingly, post-exercise identification of caffeine in PLA showed a tendency 334 
towards improved performance despite participants having ingested no active 335 
substance. Increases in this subgroup were likely beneficial, above the variation of the 336 
test (+3.7 vs. +3.0%) and very close to the overall beneficial effect of caffeine shown 337 
in the current study (~4.0%). Beedie et al. (2006) previously investigated the effects 338 
of expectation on performance; participants were informed that they had ingested 339 
either 4.5 or 9.0 mg·kg-1BM prior to exercise although caffeine was not administered 340 
on any occasion. Despite this, the authors showed a likely beneficial 2.2% in 10 km 341 
TT performance when participants believed they had ingested caffeine, which is 342 
similar to the performance increase of ~3.5% according to post-exercise caffeine 343 
identification in PLA in the current study. Taken together, these results support the 344 
notion that the belief that one has ingested an active supplement can strongly 345 
influence the outcome of an exercise task (Clark et al., 2000). Furthermore, it seems 346 
reasonable to speculate that expectation, which is highly variable among individuals, 347 
is a factor that can potentially account for some of the variability in responses to 348 
certain interventions in sports nutrition.  349 
 350 
Indeed, it is apparent that correct identification of placebo may have impeded 351 
performance with possibly harmful effects and a total of four (pre-exercise 352 
identification) and six (post-exercise identification) participants worsening 353 
performance beyond the variation of the test. The nocebo effect is directly opposite to 354 
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the placebo effect in that a negative outcome occurs following the administration of 355 
an inert intervention (Benedetti et al., 2007). This phenomenon has been shown to 356 
reduce exercise performance (Lundby et al,, 2012; Pollo et al., 2012) and increase 357 
ratings of perceived exertion (Bottoms et al., 2014), but it has been rarely addressed 358 
scientifically, particularly in sports nutrition. Interestingly, based upon our findings, it 359 
appears that correct identification of placebo by some athletes expecting to receive a 360 
potential ergogenic aid may result in the nocebo effect, possibly by frustrating their 361 
expectations. However, the opposite appeared true in individuals who believed they 362 
had ingested placebo when taking caffeine. While it remains unclear as to why and 363 
how active and non-active substances can differently modulate expectations and 364 
performance, this study provides some evidence to suggest that the nocebo effect may 365 
play a role in performance outcomes and should be accounted for within any 366 
experimental investigation or clinical intervention in sports nutrition.  367 
 368 
Correct (+4.8%) and incorrect (+7.3%) pre-exercise supplement identification in CAF 369 
resulted in performance improvements above the overall effect (+4.1%). Post-370 
exercise, incorrect placebo identification fell below this overall improvement (+3.3%) 371 
while correct identification of caffeine improved further (+6.5%). These changes are 372 
due to a number of participants changing their opinion from pre- to post-exercise, 373 
likely due to stimuli relating to the exercise (Beedie et al., 2006). The majority of the 374 
stated reasons for believing caffeine had been ingested prior to exercise were due to 375 
the sensation of caffeine associated side effects, specifically tachycardia, alertness and 376 
trembling. Additionally, a number of participants’ reasons for identifying caffeine 377 
post-exercise appear to be due to stimuli felt throughout the exercise test, namely 378 
“feeling better” or “less tired”. This was particular true with respect to the eleven 379 
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individuals who changed their opinion to caffeine, six of whom (four in CAF; two in 380 
PLA) improved their performance above the variation of the test. Thus, it could be 381 
suggested that post-exercise supplement identification may be the most accurate 382 
measurement relating to perception since it incorporates both conceptions prior to 383 
(i.e., side-effects) and during (i.e., side-effects and performance effects) the exercise. 384 
However, the main limitation of this study is that we did not determine why 385 
participants changed their opinion. Furthermore, it cannot be fully elucidated whether 386 
any participant’s change in supplement identification resulted from their performance 387 
or whether it shaped the performance itself. Nonetheless, these data support the notion 388 
that preconceptions may be further modified by factors intrinsic to exercise (Beedie et 389 
al., 2006), and thus should be taken into account. Future research should include pre- 390 
and post-exercise questionnaires including the opportunity to discuss why opinions 391 
were modified.  392 
 393 
The results of this study highlight the necessity in assessing a participants’ perception 394 
of what they have ingested in order to distinguish the true effect of a supplement from 395 
its placebo effect. Importantly, simply including a placebo group may not be 396 
sufficient to effectively blind an experiment; active nutrients and drugs, such as 397 
caffeine, beta-alanine, sodium bicarbonate and creatine, may cause side effects or 398 
changes in performance, which are clues leading subjects to identify the treatment. To 399 
avoid bias in the analysis of results, it would be prudent to test the efficacy of the 400 
blinding procedure by asking participants to identify the supplement ingested. 401 
Comprehensive assessment of data according to perceptions of the supplement 402 
ingested could allow for more definitive conclusions on the actual effects of active 403 
nutrients in sports nutrition. In contrast to the undesirable effect of preconception in 404 
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research, any such bias may prove positive in a real world setting. It would be 405 
reasonable to suggest that an athlete may benefit solely from the belief that he has 406 
ingested an active supplement, a notion previously suggested to have some scientific 407 
basis (de la Fuente-Fernandez et al., 2002; Yang et al., 2002). 408 
 409 
Perspective 410 
Correct identification of caffeine, particularly after exercise, appeared to improve 411 
cycling performance to a greater extent than the overall effect of caffeine. 412 
Furthermore, participants who believed they had ingested caffeine while ingesting 413 
placebo also appeared to improve their performance while correct identification of 414 
placebo may lead to possible impairments in performance for some individuals. 415 
Altogether, these results suggest that an individual’s perception of whether they have 416 
ingested an active supplement contributes greatly to their exercise performance, 417 
although the mechanisms by which this influences performance remain to be fully 418 
elucidated. Scientists must be encouraged to systematically test whether their blinding 419 
procedure was effective when interpreting data as this is likely a source of bias in 420 
sports nutrition. 421 
422 
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Figures 509 
Figure 1. Effect sizes compared to CON in CAF and PLA separated into subgroups 510 
based upon supplement identification pre- and post-exercise. Panel A displays CAF vs. 511 
CON pre-exercise. Panel B displays CAF vs. CON post-exercise. Panel C displays 512 
PLA vs. CON pre-exercise. Panel D displays PLA vs. CON post-exercise. 513 
 514 
Figure 2. Individual percentage change from CON in CAF (Panel A) and PLA (Panel 515 
B) organised according to supplement identification subgroups pre- and post-exercise. 516 
The grey dotted line represents the natural variation of the test (±3.0%) while the 517 
black dotted line represents the mean overall improvement with caffeine (+4.1%). The 518 
number of participants who improved above, were within, or worsened beyond the 519 
natural variation of the test in each subgroup is displayed below each graph.  520 
521 
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Table 1.1 522 
 523 
Characteristic Mean (SD) Range 
   Minimum Maximum 
Age (y)  37 (8) 18 55 
Height (cm)  1.76 (0.06) 1.60 1.89 
Body mass (kg)  74.3 (8.4) 58.9 93.0 
Experience (y)  12 (11) 1 40 
Weekly training Duration (h) 11 (5) 4 25 
 Distance (km) 272 (119) 50 500 
     
VO2max  
 
Absolute (L·min-1) 3.7 (0.5) 2.8 4.8 
Relative (ml·kg·min-1) 50.0 (6.8) 33.6 64.5 
HRmax (beats·min
-1)  182 (11) 158 201 
Wmax  Absolute (W) 329.7 (53.8) 181.4 439.0 
Habitual caffeine 
intake (mg·day-1) 
 192 (156) 1.77                          583.0
     
     
 524 
                                                 
1 Table 1. Participant characteristics 
27 
 
Table 2.2 525 
 526 
  Pre-exercise identification  Post-exercise identification 
  Correct Don’t know Wrong  Correct Don’t know Wrong 
 N 17 13 12  20 8 14 
CAF 
MPO (W) 
233.9 ± 41.1* 230.9 ± 32.6 238.2 ± 37.1^  236.4 ± 37.2* 234.1 ± 35.8 231.1 ± 39.0# 
CON 223.7 ± 40.7 230.8 ± 36.0 223.2 ± 40.3  223.2 ± 39.7 236.0 ± 43.0 223.6 ± 35.6 
CAF vs. CON % difference +4.8 ± 4.7 +0.4 ± 5.0 +7.3 ± 7.5  +6.5 ± 6.6 -0.3 ± 4.2 +3.3 ± 5.2 
MBI  
% chance of being 
beneficial/trivial/harmful 
99/1/0 13/76/11 99/1/0 
 
100/0/0 7/65/28 87/13/0 
         
 N 17 17 8  18 13 11 
PLA 
MPO (W) 
240.0 ± 40.8 226.5 ± 30.0 205.6 ± 38.3  230.5 ± 43.4 223.6 ± 36.9 229.0 ± 30.1$ 
CON 242.0 ± 36.9 221.4 ± 35.8 200.5 ± 34.4  233.8 ± 39.9 218.3 ± 42.7 221.3 ± 30.6 
PLA vs. CON % difference -1.0 ± 5.0 +3.0 ± 8.0 +2.4 ± 5.1  -1.6 ± 4.9 +3.2 ± 7.6 +3.7 ± 6.3 
MBI  
% chance of being 
beneficial/trivial/harmful 
3/72/25 62/37/1 61/37/2 
 
0/60/40 62/36/2 84/16/0 
                                                 
2 Table 2. MPO in CAF, PLA and CON, and % absolute difference from CON in CAF and PLA, when categorising individuals into their pre- and post-exercise supplement 
identification responses.  *P ≤ 0.001 from CON. ^P ≤ 0.01 from CON. #P ≤ 0.05 from CON. $P ≤ 0.06 from CON. MPO = Mean power output; CAF = Caffeine trial; PLA 
= Placebo trial; CON = Control trial; MBI = Magnitude based inferences. 
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